Scholarlink

<p>Antibiotics with activity against the widespread and difficult-to-treat metallo-β-lactamase (MBL)-producing Gram-negative bacteria are lacking, with treatment being further challenged by evolving antimicrobial resistance mechanisms. Cefiderocol monotherapy and a combination of aztreonam and avibactam (either as a single product formulation or through co-administration of ceftazidime/avibactam and aztreonam) are the preferred treatment options for infections caused by MBL-producing bacteria, including Enterobacterales, <i>Pseudomonas aeruginosa</i> and <i>Acinetobacter baumannii</i>, though their efficacy has been demonstrated in few clinical trials. Although new agents with activity against MBL-producers are in development, there is a need for further research to address the shortage of treatment options.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Confirm presence of metallo-β-lactamase-producing Gram-negative bacteria to inform treatment of infection, although clinical data are limited for current and emerging treatment options

  • 期刊论文

  • 发表日期：

    2025年8月11日

查看全文
  • Aisling McGuigan

摘要

Antibiotics with activity against the widespread and difficult-to-treat metallo-β-lactamase (MBL)-producing Gram-negative bacteria are lacking, with treatment being further challenged by evolving antimicrobial resistance mechanisms. Cefiderocol monotherapy and a combination of aztreonam and avibactam (either as a single product formulation or through co-administration of ceftazidime/avibactam and aztreonam) are the preferred treatment options for infections caused by MBL-producing bacteria, including Enterobacterales, Pseudomonas aeruginosa and Acinetobacter baumannii, though their efficacy has been demonstrated in few clinical trials. Although new agents with activity against MBL-producers are in development, there is a need for further research to address the shortage of treatment options.